This study investigates the effectiveness of self-nanoemulsifying drug delivery system (SNEDDS) in improving voriconazole transcorneal permeability. Voriconazole-SNEDDS was prepared with isopropyl myristate, PEG 400, Tween 80® and Span 80® and was subjected for physicochemical characterization after reconstitution with NaCl 0.9% (1/9; v/v). In-vitro antifungal activity was assessed and compared with the marketed formulation. In-vivo studies, namely ocular irritation test via modified Draize test and pharmacokinetic study, were investigated using rabbit as animal model. Voriconazole-SNEDDS presented a droplet size of 21.353±0.065nm, a polydispersity index of 0.123±0.003, a pH of 7.205±0.006 and an osmolarity of 342.667±2.517mOsmol/l after reconstitution with NaCl 0.9%. Voriconazole-SNEDDS minimum inhibitory concentration (MIC90 ) was similar to the one of marketed formulation for Candida species while it was significantly lower (P<0.001) for Aspergillus fumigatus. Draize test revealed that Voriconazole-SNEDDS was safe for ocular administration. Voriconazole maximum concentration (5.577±0.852µg/ml) from SNEDDS was higher than marketed formulation (Cmax =4.307±0.623µg/ml), and the Tmax was delayed to 2h. The area under the concentration-time curve value of Voriconazole-SNEDDS was improved by 2.419-fold. Our results suggest that SNEDDS is a promising carrier for voriconazole ocular delivery and this encourages further clinical studies.